Turning Point Therapeutics, Inc.

TPTX · NASDAQ
Analyze with AI
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Market Cap$1,948,248$4,976,815$1,502,742$431,710
- Cash$427,879$554,101$48,188$101,029
+ Debt$5,579$3,819$5,055$0
Enterprise Value$1,525,948$4,426,533$1,459,609$330,681
Revenue$30,829$25,000$0$0
% Growth23.3%
Gross Profit$30,829$0$0$0
% Margin100%0%
EBITDA-$232,584-$154,899-$70,552-$24,646
% Margin-754.4%-619.6%
Net Income-$236,551-$157,292-$72,131-$24,785
% Margin-767.3%-629.2%
EPS Diluted-5.79-3.85-2.99-1.66
% Growth-50.4%-28.8%-80.1%
Operating Cash Flow-$153,885-$82,793-$57,757-$23,533
Capital Expenditures-$2,427-$1,264-$1,744-$302
Free Cash Flow-$156,312-$84,057-$59,501-$23,835
Turning Point Therapeutics, Inc. (TPTX) Financial Statements & Key Stats | AlphaPilot